Michael Marmura is a Neurology physician affiliated with Thomas Jefferson University. OpenAlex indexes 162 publications with 2,675 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
81%Calcitonin gene-related peptide (CGRP) antagonists19.2%Aimovig Autoinjector39%Emgality Pen39%Ajovy Syringe20%Ajovy Autoinjector3%Part D<11 patientsSerotonin-1b and Serotonin-1d Receptor Agonist9.8%Sumatriptan Succinate48%Rizatriptan24%Eletriptan Hbr17%Naratriptan Hcl11%Part D<11 patients+ 22 more classes in this area
Musculoskeletal
9.3%Central alpha-2 Adrenergic Agonist2.7%Tizanidine Hcl100%Part D≥14 patientsNonsteroidal Anti-inflammatory Drug2.4%Diclofenac Sodium34%Nabumetone27%Indomethacin20%Naproxen20%Part D<11 patients+ 3 more classes in this area
Cardiovascular
5.4%Antiarrhythmic1.8%Mexiletine Hcl100%Part D≥13 patientsAngiotensin receptor blocker (ARB)1.7%Candesartan Cilexetil100%Part D≥17 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
The Journal of Headache and Pain
2024 - Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized <scp>PROMISE</scp> ‐2 trial
Headache The Journal of Head and Face Pain
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”